argenx
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: Efgartigimod concentrate for solution for infusion 20 mg/mL
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 69
- Registration Number
- NCT04980495
- Locations
- 🇺🇸
Investigator Site 9 - 0010006, Boca Raton, Florida, United States
🇺🇸Investigator Site 17 - US0010012, Philadelphia, Pennsylvania, United States
🇺🇸Investigator Site 10 - US0010007, Carlsbad, California, United States
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: Efgartigimod IV
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 12
- Registration Number
- NCT04833894
- Locations
- 🇺🇸
Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸University of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville, Virginia, United States
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: efgartigimod PH20 SC
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- argenx
- Target Recruit Count
- 183
- Registration Number
- NCT04818671
- Locations
- 🇩🇪
Investigator Site 26 - DE490009, Münster, Germany
🇬🇪Investigator Site 1 - GEO9950001, Tbilisi, Georgia
🇬🇪Investigator Site 33 - GEO9950016, Tbilisi, Georgia
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Biological: efgartigimod PH20 SC
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 173
- Registration Number
- NCT04812925
- Locations
- 🇹🇳
Investigator site 2160002, Tunis, Tunisia
🇨🇱Investigator site 560002, Santiago, Chile
🇦🇺Investigator Site 0610003, West Perth, Australia
Efgartigimod Expanded Access for Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- argenx
- Registration Number
- NCT04777734
- Locations
- 🇺🇸
Investigator site 12 - Approved for Marketing, Chicago, Illinois, United States
🇺🇸Investigator Site 6 - Approved for Marketing, New Hyde Park, New York, United States
🇺🇸Investigator site 2 - Approved for Marketing, Henrico, Virginia, United States
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: efgartigimod PH20 SCBiological: efgartigimod IV
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 110
- Registration Number
- NCT04735432
- Locations
- 🇺🇸
Investigator site 2 - US0010108, Boca Raton, Florida, United States
🇺🇸Investigator Site 43 - 0010019, Cleveland, Ohio, United States
🇵🇱Investigator Site 22 - PL0480005, Kraków, Poland
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Biological: Efgartigimod PH20 SCOther: Placebo PH20 SC
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- argenx
- Target Recruit Count
- 207
- Registration Number
- NCT04687072
- Locations
- 🇺🇸
Investigator site 0010036, Los Angeles, California, United States
🇺🇸Investigator site 0010040, Columbus, Ohio, United States
🇺🇸Investigator Site 0010115, Pittsburgh, Pennsylvania, United States
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Conditions
- Pemphigus FoliaceusPemphigus Vulgaris
- Interventions
- Biological: efgartigimod PH20 SC
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 183
- Registration Number
- NCT04598477
- Locations
- 🇺🇸
Investigator site 124 - US0010092, Redwood City, California, United States
🇺🇸Investigator site 1 - US0010087, Boca Raton, Florida, United States
🇺🇸Investigator site 91 - US0010109, Orlando, Florida, United States
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Conditions
- Pemphigus VulgarisPemphigus Foliaceus
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 222
- Registration Number
- NCT04598451
- Locations
- 🇬🇧
Investigator site 117 - UK0440021, Birmingham, United Kingdom
🇧🇬Investigator site 30 - BG350012, Pleven, Bulgaria
🇧🇬Investigator site 31 - BG3590013, Plovdiv, Bulgaria
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Biological: efgartigimod PH20 SCBiological: efgartigimod IV
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- argenx
- Target Recruit Count
- 54
- Registration Number
- NCT04564066
- Locations
- 🇳🇱
Study Site 1, Groningen, Netherlands